CB-012, developed by Caribou Biosciences, Inc., is an allogeneic CAR-T cell therapy targeting CLL-1, specifically designed for patients with relapsed or refractory acute myeloid leukemia (AML). The therapy aims to address a significant unmet need in the AML market, particularly for patients who have limited treatment options after multiple lines of therapy. The competitive landscape includes other CAR-T therapies and emerging treatments targeting similar patient populations. However, the unique CRISPR-editing technology may provide a differentiation point in terms of efficacy and safety profile. The termination of this trial due to sponsor decision and pipeline reprioritization raises concerns regarding the asset's future and may indicate a strategic shift within Caribou's portfolio, necessitating further diligence on their remaining assets and overall pipeline strategy.